Loading…
Xencor, Inc. is projected to rise to $18.36 by 2027, a +16% move from its current price of $15.85. XNCR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $15.38 | $15.85 | $16.32 | -0.03% |
| Jul 15 | $15.19 | $15.84 | $16.52 | -0.06% |
| Jul 16 | $15.04 | $15.84 | $16.67 | -0.08% |
| Jul 17 | $14.92 | $15.83 | $16.80 | -0.11% |
| Jul 18 | $14.81 | $15.83 | $16.91 | -0.14% |
| Jul 19 | $14.72 | $15.82 | $17.02 | -0.17% |
| Jul 20 | $14.63 | $15.82 | $17.11 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.63 | $15.82 | $17.11 | -0.19% |
| Week 2 | $14.13 | $15.79 | $17.64 | -0.39% |
| Week 3 | $13.76 | $15.76 | $18.05 | -0.58% |
| Week 4 | $13.44 | $15.73 | $18.40 | -0.78% |
| Week 5 | $13.17 | $15.70 | $18.70 | -0.97% |
| Week 6 | $12.93 | $15.67 | $18.98 | -1.16% |
| Week 7 | $12.71 | $15.64 | $19.24 | -1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. It advances a diverse pipeline of antibody-based therapies and bispecifics intended to address multiple disease areas.
The company was incorporated in 1997 and is headquartered in Pasadena, California. Its portfolio features marketed products Ultomiris to treat atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder; and Monjuvi for relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb-based antibodies and a broad set of other programs, including XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, XmAb657, Xaluritamig, ASP2138, JNJ-9401, Obexelimab, Tobevibart, Zaltenibart, Teropavimab and zinlirvimab, among others.
These agents collectively illustrate a focus on engineered antibodies and bispecifics across oncology and autoimmune indications.
Xencor, Inc. trades as XNCR and currently shows a price of $16.46 with a market capitalization of $1.22B, ranking 2414 by market cap. The stock’s price has a 30-day range of $13.42 to $20.19, reflecting near-term volatility within a broader upward trajectory suggested by the long-range forecast.
Near-term dynamics position the stock around the current price, while longer-run projections point to meaningful appreciation over time. The forecasted path shows average prices rising across years, with 2026 average at $16.46 and 2030 average at $29.20, extending to $73.27 by 2040 and $158.81 by 2050, indicating substantial upside if the trajectory holds.
Across the horizon, expected returns grow from 0% in 2026 to higher positives in later years, with 2027-2050 ROIs of 14.4%, 20.2%, 36%, 77.4%, 111.5%, 128.5%, 127.3%, 146.6%, 177.5%, 345.1%, and 864.8% respectively, all within a bullish sentiment framework for the multi-year outlook.
A major floor 41.6% below — a decisive break under it would weaken the trend.
The nearest floor, 29.3% below — buyers have tended to step in here.
The nearest ceiling, 3.8% above — a clean break opens room to run.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key XNCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XNCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.80 | Buy | $15.83 | Buy |
| MA 10 | $15.61 | Buy | $15.44 | Buy |
| MA 20 | $14.38 | Buy | $14.63 | Buy |
| MA 50 | $12.90 | Buy | $13.48 | Buy |
| MA 100 | $12.54 | Buy | $13.03 | Buy |
| MA 200 | $13.31 | Buy | $12.92 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.28 | Neutral |
| Stoch RSI (14) | 11.03 | Buy |
| CCI (20) | 76.94 | Neutral |
| Williams %R (14) | -24.90 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | 12.57 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 75.10 | Neutral |
| TRIX (15) | 1.01 | Buy |
| Awesome (5,34) | 2.54 | Buy |
| Ultimate (7,14,28) | 57.21 | Neutral |
| Momentum (10) | 1.11 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 16.25 | Sell |
| ADX (14) | 29.30 | Buy |
| ATR (14) | 0.41 | Info |
The 30-day technical picture is bullish. RSI14 sits at 70, suggesting strong momentum, while the stock trades above its near-term moving averages (SMA50 at $12.76 and SMA200 at $13.26). Support sits at $11.21 and resistance at $16.46, with the 30-day price range spanning from $13.42 to $20.19.
These indicators imply a constructive setup in the near term, with upside potential if the price remains above the support level and continues to test the $16.46 resistance in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.41 | $15.85 | $19.89 | 0% | Neutral | |
| $14.50 | $18.36 | $24.66 | +16% | Neutral | |
| $15.10 | $19.70 | $27.54 | +24% | Bullish | |
| $16.91 | $22.64 | $32.64 | +43% | Bullish | |
| $21.35 | $29.24 | $43.26 | +84% | Bullish | |
| $25.15 | $35.16 | $53.20 | +122% | Bullish | |
| $26.95 | $38.39 | $59.29 | +142% | Bullish | |
| $26.34 | $38.21 | $60.10 | +141% | Bullish | |
| $28.43 | $41.96 | $67.11 | +165% | Bullish | |
| $31.72 | $47.59 | $77.32 | +200% | Bullish | |
| $47.85 | $77.35 | $134.17 | +388% | Bullish | |
| $92.13 | $169.64 | $323.53 | +970% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $10.41 | $15.85 | $19.24 | +0.00% |
| August 2026 | $13.43 | $15.88 | $19.31 | +0.19% |
| September 2026 | $12.97 | $15.45 | $19.02 | -2.69% |
| October 2026 | $13.12 | $15.73 | $19.56 | +1.82% |
| November 2026 | $13.28 | $16.02 | $20.09 | +1.85% |
| December 2026 | $12.98 | $15.74 | $19.89 | -1.76% |
Click any year to see its month-by-month XNCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect XNCR to range from $10.41 to $19.89 through 2026. The $15.85 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The XNCR price prediction for 2027 points to an average of $18.36 (low $14.50, high $24.66) — a potential gain of +16% on today's $15.85. A consolidation phase looks the most probable path here.
In 2028, XNCR is projected to trade between $15.10 and $27.54, averaging $19.70 — a potential gain of +24% from today's $15.85. That is up +7% on the projected 2027 average. Momentum favours further upside here.
Xencor, Inc.'s 2029 outlook centres on $22.64, within a $16.91 to $32.64 range. That is up +15% on the projected 2028 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, XNCR could reach as high as $43.26, with a base case around $29.24 and support toward $21.35 — roughly +84% from $15.85. Momentum favours further upside here.
Expect XNCR to range from $25.15 to $53.20 through 2031. The $35.16 average target implies a +122% move from current prices. That is up +20% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The XNCR price prediction for 2032 points to an average of $38.39 (low $26.95, high $59.29) — a potential gain of +142% on today's $15.85. Momentum favours further upside here.
In 2033, XNCR is projected to trade between $26.34 and $60.10, averaging $38.21 — a potential gain of +141% from today's $15.85. That is 0% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Xencor, Inc.'s 2034 outlook centres on $41.96, within a $28.43 to $67.11 range. That is up +10% on the projected 2033 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2035, XNCR could reach as high as $77.32, with a base case around $47.59 and support toward $31.72 — roughly +200% from $15.85. Buyers look set to stay in control over this stretch.
Expect XNCR to range from $47.85 to $134.17 through 2040. The $77.35 average target implies a +388% move from current prices. That is up +63% on the projected 2035 average. Momentum favours further upside here.
The XNCR price prediction for 2050 points to an average of $169.64 (low $92.13, high $323.53) — a potential gain of +970% on today's $15.85. Buyers look set to stay in control over this stretch.
Investing $1,000 in XNCR today (≈ 63.091483 XNCR) could be worth
$10,702.76
+$9,702.76 (+970%) by 2050 · US Dollar
Based on the average projected XNCR price of $169.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XNCRwould be worth at today's price.
$1,000 invested in XNCR on Jul 10, 2025 (≈ 107.758624 XNCR) would be worth
$1,707.97
+$707.97 (+70.8%) today · 1.71× · US Dollar
Based on a XNCR entry price of $9.28 vs. today's $15.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15 | $1,056.67 | +5.7% |
| 1 month ago | $11.83 | $1,339.81 | +34.0% |
| 3 months ago | $12.42 | $1,276.17 | +27.6% |
| 6 months ago | $14.17 | $1,118.56 | +11.9% |
| 1 year ago | $9.28 | $1,707.97 | +70.8% |
| All time (5.0y) ago | $32.9 | $481.76 | -51.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XNCR forecast.
Our base-case forecast reaches $32.00 around 2031.
Implied market cap at $32.00: $2.37B
The multi-year forecast points to a persistent bullish trajectory, with the average price climbing from $16.46 in 2026 to $29.20 in 2030 and reaching $73.27 by 2040, then $158.81 on average in 2050. The corresponding ROI grows from 0% in 2026 to 77.4% in 2030, 345.1% in 2040, and 864.8% in 2050, underscoring substantial upside under the assumed conditions. Sentiment across the forecast years shifts to bullish starting in 2027 and remains so through 2050.
Key risk factors include the inherent uncertainty of clinical-stage drug development, regulatory outcomes, and market dynamics. While the numbers portray a strong longer-term upside, they are estimates and not guarantees, and actual results may differ due to scientific, regulatory, and market variables.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $29.20, with a min of $21.13 and a max of $43.64; ROI is 77.4% and the sentiment is BULLISH.
Forecasts indicate bullish momentum over time with average prices rising to $29.20 by 2030 and $158.81 by 2050, and ROIs of 77.4% (2030) up to 864.8% (2050). Still, 2026 projects a 0% ROI and the outlook carries inherent uncertainty.
Yes. The forecast max reaches $129.06 in 2040 and $308.40 in 2050, suggesting $100 could be exceed in the 2040–2050 window, though these are not guaranteed.
Current price is $16.46 and market cap is $1.22B; the stock rank is 2414.
Bullish sentiment with RSI14 at 70, SMA50 at $12.76, SMA200 at $13.26, support at $11.21, and resistance at $16.46. The 30-day range is $13.42–$20.19, and annualized volatility is 60%.
Xencor, Inc. Community Discussion
0Share your Xencor, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.